TY - JOUR
T1 - Effect of omeprazole and sucralfate on gastrointestinal injury in a fasting/NSAID model
AU - Bishop, Rebecca C.
AU - Kemper, Ann M.
AU - Wilkins, Pamela A.
AU - McCoy, Annette M.
N1 - Funding was provided under the USDA Section 15 Animal Health and Disease Program (ILLU-888-949). We thank Dr Ceara Suther, Oliva Downs, Dr Ashley Parsley and Dr Kyle Grogger for assistance with gastroscopies and animal care.
PY - 2022/7
Y1 - 2022/7
N2 - Background: Equine gastric ulcer syndrome (EGUS) is a common and significant cause of morbidity in horses, with a range of clinical signs, including inappetence, colic and poor performance. Hospitalised horses are exposed to factors that may induce EGUS, including fasting and nonsteroidal anti-inflammatory drug (NSAID) administration, and may be at risk for development of squamous (ESGD) and glandular gastric disease (EGGD). Prophylactic anti-ulcer medication is often prescribed for these patients, but drug selection is complicated by different aetiology and response to treatment of ESGD and EGGD. Objectives: To establish the efficacy of sucralfate or omeprazole used prophylactically in horses exposed to a combined feed-fast and NSAID administration EGUS induction protocol. We hypothesised that these drugs would be equally effective for prevention of gastric lesions in the experimental cohort. Study design: Randomised crossover experimental design. Methods: Horses (n = 14) received either omeprazole (1 mg/kg PO q24h) or sucralfate (20 mg/kg PO q8h) while undergoing the feed-fast/NSAID protocol, allowed an 8-week washout period, and then administered the alternate treatment. Serial gastroscopy, ultrasound and haematology documented treatment effects. Results: ESGD and EGGD score increased over time under both treatments. There was a significant effect of treatment on EGGD scores (P <.001), with post-treatment EGGD scores higher for horses receiving sucralfate (median 3; IQR 2.25,3) than omeprazole (1; 1,1). The effect of treatment on ESGD scores just achieved significance (P =.05), with post-treatment ESGD scores higher for sucralfate (4; 3,4) than omeprazole (2; 2,3). Main limitations: This study was performed in healthy horses, and response to treatment may differ in horses with clinical illness. Additional investigation in a larger population may be required to detect significant differences in other clinical parameters. Conclusions: Omeprazole was superior to sucralfate for mitigating gastric lesion severity in healthy horses exposed to a feed-fast/NSAID model.
AB - Background: Equine gastric ulcer syndrome (EGUS) is a common and significant cause of morbidity in horses, with a range of clinical signs, including inappetence, colic and poor performance. Hospitalised horses are exposed to factors that may induce EGUS, including fasting and nonsteroidal anti-inflammatory drug (NSAID) administration, and may be at risk for development of squamous (ESGD) and glandular gastric disease (EGGD). Prophylactic anti-ulcer medication is often prescribed for these patients, but drug selection is complicated by different aetiology and response to treatment of ESGD and EGGD. Objectives: To establish the efficacy of sucralfate or omeprazole used prophylactically in horses exposed to a combined feed-fast and NSAID administration EGUS induction protocol. We hypothesised that these drugs would be equally effective for prevention of gastric lesions in the experimental cohort. Study design: Randomised crossover experimental design. Methods: Horses (n = 14) received either omeprazole (1 mg/kg PO q24h) or sucralfate (20 mg/kg PO q8h) while undergoing the feed-fast/NSAID protocol, allowed an 8-week washout period, and then administered the alternate treatment. Serial gastroscopy, ultrasound and haematology documented treatment effects. Results: ESGD and EGGD score increased over time under both treatments. There was a significant effect of treatment on EGGD scores (P <.001), with post-treatment EGGD scores higher for horses receiving sucralfate (median 3; IQR 2.25,3) than omeprazole (1; 1,1). The effect of treatment on ESGD scores just achieved significance (P =.05), with post-treatment ESGD scores higher for sucralfate (4; 3,4) than omeprazole (2; 2,3). Main limitations: This study was performed in healthy horses, and response to treatment may differ in horses with clinical illness. Additional investigation in a larger population may be required to detect significant differences in other clinical parameters. Conclusions: Omeprazole was superior to sucralfate for mitigating gastric lesion severity in healthy horses exposed to a feed-fast/NSAID model.
KW - equine gastric ulcer syndrome (EGUS)
KW - equine glandular gastric disease (EGGD)
KW - equine squamous gastric disease (ESGD)
KW - gastroprotectant
KW - horse
KW - nonsteroidal anti-inflammatory drug (NSAID)
KW - proton pump inhibitor (PPI)
UR - http://www.scopus.com/inward/record.url?scp=85118664632&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85118664632&partnerID=8YFLogxK
U2 - 10.1111/evj.13534
DO - 10.1111/evj.13534
M3 - Article
C2 - 34719063
AN - SCOPUS:85118664632
SN - 0425-1644
VL - 54
SP - 829
EP - 837
JO - Equine veterinary journal
JF - Equine veterinary journal
IS - 4
ER -